Siemens Healthineers announced that it is now shipping worldwide its laboratory-based total antibody test(1) to detect the presence of SARS-CoV-2 IgM and IgG antibodies in blood. The test received the CE mark and data has demonstrated 100 percent sensitivity(2) and 99.8 percent specificity. 
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its wearable biosensor (Philips Biosensor BX100) to help manage confirmed and suspected COVID-19 patients in the hospital. 
Gloucestershire Hospitals NHS Foundation Trust, located in the United Kingdom, has successfully gone live with the latest addition to its Allscripts electronic health record, despite the ongoing novel coronavirus outbreak. Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced Clinical Trial Accelerator on Philips HealthSuite. This new tailored set of capabilities allows life science organizations to integrate, analyze and store clinical and patient-reported data from multiple sources, providing actionable insights for better, faster decision-making. 
Seven NHS Trusts are using technology developed by WiFi SPARK in response to an urgent request from leading NHS Trusts to find a way to connect hospital patients with their loved ones during the coronavirus outbreak. 
Highland Marketing's board of NHS IT and industry leaders has recognised the uptick in health tech adopting during the Covid-19 crisis. But at their most recent meeting, members argued that a second wave of innovation is now needed; alongside a plan to embed change in the health care system. 
The bioinformatics company Biomax, headquartered in Planegg, Germany, makesitssemantic search platform AILANI available free of charge to research institutes around the world in order to support the rapid and successful search for drugs and suitable vaccinesagainst COVID-19 infections.